All Posts

HIV treatment landscape
HIV Treatment Landscape and A New Approach

The Human immunodeficiency virus (HIV) cases have grown to pandemic extents since the first case of acquired immunodeficiency syndrome (AIDS) was reported in 1981. CDC estimates that approximately 1.1 million people in the U.S. are living with HIV today. About 15 per cent of them (1 in 7) are unaware of their infec...

Find More

Pharma News
Turalio gets FDA approval; Sosei Heptares, Takeda forms an R&D pact

FDA approves first Tenosynovial giant cell tumour treatment Turalio (Pexidartinib) The US FDA has given its approval to Turalio (pexidartinib) capsules for the treatment of symptomatic tenosynovial giant cell tumour (TGCT) associated with severe morbidity or functional limitations that surgery has failed to impr...

Find More

Epilepsy drug resistance
DRUG-RESISTANT EPILEPSY

Failure in suppressing epilepsy; steps away from seizure-freedom Epilepsy, a central nervous system disorder that hinders the normal functioning of the brain, and leads to abnormality and loss of awareness. It affects over 70 million people worldwide, wherein nearly a quarter of patients with seizures have drug-...

Find More

Diabetic Gastroparesis Market
Diabetic Gastroparesis Market Outlook

Gastroparesis is a condition that affects the movement of the food in the stomach and intestines and causes distress leading to bloating, nausea, and heartburn. If the condition is due to Diabetes in the patients, it is called Diabetic Gastroparesis. According to the American Diabetes Association (ADA), Gastropares...

Find More

FDA approval for Nubeqa; Biodesix, Immodulon collaborates on Cancer treatment; Cancer asset rights to Alligator Bioscience

Bayer and Orion's Nubeqa gets FDA recommendations for Prostate Cancer The U.S. FDA has given its nod to Nubeqa (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nubeqa is a steroidal androgen receptor inhibitor (ARi), and its recommendation came afte...

Find More

HIV-Drug Resistance
Frightening Surge in HIV-drug Resistance: The Biggest Challenge Ahead

In a survey conducted by WHO, globally, 37.9 million people were tested positively living with HIV in 2018. Out of which, 62% (23.3 million) of the people were receiving antiretroviral treatment by the end of 2018. WHO, in addition to all the other Health organizations are working towards achieving the WHO/UNAIDS 9...

Find More

pharma News
CHPM’s positive approval for 13 Medicines; NICE approval for AstraZeneca’s Olaparib; Exact Sciences to buy Genomic Health

CHMP opines positively for 13 Drugs for a variety of disease The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has endorsed the use of 13 medicinal drugs for a variety of indications. These include five new medications and eight existing ones whose use is extended ...

Find More

Hepatitis B Market Size
Global Hepatitis B Market Size

1 in every 100,000 persons get infected with Hepatitis B virus every year at a stable rate from the past three decades. Moreover, the WHO estimated that there are more than 2 billion HBV infected people and about 378 million chronic Hepatitis B virus carriers worldwide. Hepatitis B, often life-threatening, is a...

Find More

Hepatitis
World Hepatitis Day

World Hepatitis Day is observed on 28 July of every year, aims to bring the world together to raise the awareness of the global burden of viral hepatitis and bring real change. Hepatitis B virus is a blood-borne and transmitted sexually by the virus, which is acquired by percutaneous and exposure to blood or ot...

Find More

Idiopathic Pulmonary Fibrosis Market Landscape and Forecast
Idiopathic Pulmonary Fibrosis Market Landscape and Forecast

According to NIH, Idiopathic Pulmonary Fibrosis prevalent cases are estimated to be 13 to 20 per 100,000 people worldwide, making it’s a rare but severe lung disease.Idiopathic Pulmonary Fibrosis (IPF) is progressive and chronic scarring of lung tissues hampering the transport of the oxygen into the bloodstream. T...

Find More